{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:56:49Z","timestamp":1790603809483,"version":"4.1.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jinf.2026.106821","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:21:33Z","timestamp":1784676093000},"page":"106821","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cefiderocol in clinical practice: From randomised trials to real-world evidence in the management of multidrug-resistant Gram-negative bacterial infections"],"prefix":"10.1016","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0989-9653","authenticated-orcid":false,"given":"Francesca","family":"Di Bartolomeo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1031-9504","authenticated-orcid":false,"given":"Matteo","family":"Augello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4498-4828","authenticated-orcid":false,"given":"Giulia","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jinf.2026.106821_bib1","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S1473-3099(25)00118-5","article-title":"The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance","volume":"25","author":"Sati","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2026.106821_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.101034","article-title":"Cefiderocol: Clinical application and emergence of resistance","volume":"72","author":"Wang","year":"2024","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.jinf.2026.106821_bib3","doi-asserted-by":"crossref","first-page":"S552","DOI":"10.1093\/cid\/ciz828","article-title":"Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin","volume":"69","author":"Katsube","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.jinf.2026.106821_bib4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.jinf.2026.106821_bib5","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.jinf.2026.106821_bib6","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1473-3099(25)00469-4","article-title":"Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial","volume":"26","author":"Paterson","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2026.106821_bib7","doi-asserted-by":"crossref","first-page":"108305","DOI":"10.1016\/j.ijid.2025.108305","article-title":"Real-world use of cefiderocol as monotherapy or combination therapy for the treatment of Gram-negative bacterial infections: the multicentre retrospective CEFI-BAC study","volume":"163","author":"Augello","year":"2025","journal-title":"Int J Infect Dis"},{"issue":"9","key":"10.1016\/j.jinf.2026.106821_bib8","first-page":"1485","article-title":"Outcome of patients with carbapenem-resistant Acinetobacter baumannii infections treated with cefiderocol: A multicenter observational study, J Infect","volume":"16","author":"Cal\u00f2","year":"2023","journal-title":"Public Health"},{"issue":"9","key":"10.1016\/j.jinf.2026.106821_bib9","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s40121-024-01016-y","article-title":"Use of Cefiderocol in Adult Patients: descriptive analysis from a prospective, multicenter, cohort study","volume":"13","author":"Giacobbe","year":"2024","journal-title":"Infect Dis Ther"},{"issue":"1","key":"10.1016\/j.jinf.2026.106821_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.106376","article-title":"G.I.G.I.e.I. network, Real-world multicentre study of cefiderocol treatment of immunocompromised patients with infections caused by multidrug-resistant Gram-negative bacteria: CEFI-ID","volume":"90","author":"Soueges","year":"2025","journal-title":"J Infect"},{"issue":"1","key":"10.1016\/j.jinf.2026.106821_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106825","article-title":"Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19","volume":"62","author":"Russo","year":"2023","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"10.1016\/j.jinf.2026.106821_bib12","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3892\/br.2025.2034","article-title":"Real-world effectiveness and safety of cefiderocol in critically ill patients with MDR Gram-negative infections: results from a retrospective study","volume":"23","author":"Marino","year":"2025","journal-title":"Biomed Rep"},{"key":"10.1016\/j.jinf.2026.106821_bib13","doi-asserted-by":"crossref","first-page":"S538","DOI":"10.1093\/cid\/ciz826","article-title":"Cefiderocol: discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin","volume":"69","author":"Sato","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.jinf.2026.106821_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2020.115012","article-title":"Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units","volume":"97","author":"Golden","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"13","key":"10.1016\/j.jinf.2026.106821_bib15","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s40265-021-01580-4","article-title":"Cefiderocol: a review in serious gram-negative bacterial infections","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.jinf.2026.106821_bib16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40265-019-1055-2","article-title":"Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative bacilli","volume":"79","author":"Zhanel","year":"2019","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.jinf.2026.106821_bib17","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01454-17","article-title":"Antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against gram-negative bacteria","volume":"62","author":"Ito","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.jinf.2026.106821_bib18","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/jcph.841","article-title":"Cefiderocol, a siderophore cephalosporin for gram-negative bacterial infections: Pharmacokinetics and safety in subjects with renal impairment","volume":"57","author":"Katsube","year":"2017","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.jinf.2026.106821_bib19","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3390\/antibiotics10060649","article-title":"Cefiderocol in critically Ill patients with multi-drug resistant pathogens: real-life data on Pharmacokinetics and microbiological surveillance","volume":"10","author":"K\u00f6nig","year":"2021","journal-title":"Antibiotics"},{"issue":"5","key":"10.1016\/j.jinf.2026.106821_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2025.107465","article-title":"Cefiderocol pharmacokinetics in critically-ill patients receiving extra-corporeal membrane oxygenation (ECMO)","volume":"65","author":"Koenig","year":"2025","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"10.1016\/j.jinf.2026.106821_bib21","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1093\/jac\/dkab280","article-title":"Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia","volume":"76","author":"Katsube","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.jinf.2026.106821_bib22","article-title":"Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistant, JAC Antimicrob Resist","volume":"6","author":"Shields","year":"2024"},{"issue":"11","key":"10.1016\/j.jinf.2026.106821_bib23","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.3390\/biomedicines12112532","article-title":"Cefiderocol in Combating Carbapenem-Resistant","volume":"12","author":"Yousefi","year":"2024","journal-title":"Biomedicines"},{"issue":"7","key":"10.1016\/j.jinf.2026.106821_bib24","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1089\/mdr.2019.0298","article-title":"Activity of cefiderocol against","volume":"26","author":"Iregui","year":"2020","journal-title":"Microb Drug Resist"},{"issue":"3","key":"10.1016\/j.jinf.2026.106821_bib25","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.03496-22","article-title":"Cefiderocol resistance in Klebsiella pneumoniae Is Linked to SHV extended-spectrum \u03b2-Lactamase activities and functional loss of the outer membrane porin OmpK35","volume":"11","author":"Moon","year":"2023","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jinf.2026.106821_bib26","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jgar.2023.06.003","article-title":"Rapid development of cefiderocol resistance in a carbapenem-resistant Pseudomonas aeruginosa isolate associated with mutations in the pyoverdine biosynthesis pathway","volume":"34","author":"Brakert","year":"2023","journal-title":"J Glob Antimicrob Resist"},{"issue":"1","key":"10.1016\/j.jinf.2026.106821_bib27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00284-025-04597-0","article-title":"J. Yasbolaghi Sharahi, Cefiderocol: a comprehensive review of Chemistry, mechanisms of resistance, and clinical applications in the era of multidrug resistance","volume":"83","author":"Roustaye Gourabi","year":"2025","journal-title":"Curr Microbiol"},{"issue":"27","key":"10.1016\/j.jinf.2026.106821_bib28","doi-asserted-by":"crossref","first-page":"12519","DOI":"10.1039\/D5SC02122G","article-title":"Cefiderocol \"under siege\"? Understanding the rise of NDM-mediated resistance to novel agents","volume":"16","author":"Warecki","year":"2025","journal-title":"Chem Sci"},{"issue":"12","key":"10.1016\/j.jinf.2026.106821_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics11121681","article-title":"Synergistic Effect of Clinically Available Beta-Lactamase Inhibitors Combined with Cefiderocol against Carbapenemase-Producing Gram-Negative Organisms","volume":"11","author":"Bianco","year":"2022","journal-title":"Antibiotics"},{"issue":"9","key":"10.1016\/j.jinf.2026.106821_bib30","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1093\/jac\/dkac221","article-title":"Evolution of \u03b2-lactamase-mediated cefiderocol resistance","volume":"77","author":"Fr\u00f6hlich","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"10.1016\/j.jinf.2026.106821_bib31","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01221-20","article-title":"Cefiderocol resistance in acinetobacter baumannii: roles of \u03b2-Lactamases, siderophore receptors, and penicillin binding protein 3","volume":"64","author":"Malik","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"30","key":"10.1016\/j.jinf.2026.106821_bib32","doi-asserted-by":"crossref","first-page":"21328","DOI":"10.1039\/D4RA04302B","article-title":"Cefiderocol susceptibility endows hope in treating carbapenem-resistant","volume":"14","author":"Basu","year":"2024","journal-title":"RSC Adv"},{"issue":"6","key":"10.1016\/j.jinf.2026.106821_bib33","article-title":"Heteroresistance to cefiderocol in carbapenem-resistant","volume":"11","author":"Longshaw","year":"2023","journal-title":"Microbiol Spectr"},{"issue":"2","key":"10.1016\/j.jinf.2026.106821_bib34","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.cmi.2023.08.029","article-title":"Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis","volume":"30","author":"Karakonstantis","year":"2024","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"10.1016\/j.jinf.2026.106821_bib35","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.jinf.2026.106821_bib36","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/cid\/ciac078","article-title":"Cefiderocol for the treatment of infections due to Metallo-B-lactamase-producing pathogens in the CREDIBLE-CR and APEKS-NP phase 3 randomized studies","volume":"75","author":"Timsit","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.jinf.2026.106821_bib37","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s40121-022-00598-9","article-title":"Outcomes with Cefiderocol treatment in patients with bacteraemia enrolled into prospective phase 2 and Phase 3 randomised clinical studies","volume":"11","author":"Paterson","year":"2022","journal-title":"Infect Dis Ther"},{"issue":"6","key":"10.1016\/j.jinf.2026.106821_bib38","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s10096-025-05108-6","article-title":"Effectiveness and safety of cefiderocol treatment in patients with Gram-negative bacterial infections in Spain in the early access programme: results of the PERSEUS study","volume":"44","author":"Torre-Cisneros","year":"2025","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jinf.2026.106821_bib39","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.2147\/IDR.S475462","article-title":"Effectiveness and safety of cefiderocol in clinical practice for treatment of patients with gram-negative bacterial infections: US interim results of the PROVE study","volume":"17","author":"Clancy","year":"2024","journal-title":"Infect Drug Resist"},{"issue":"11","key":"10.1016\/j.jinf.2026.106821_bib40","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1093\/jac\/dkad298","article-title":"Cefiderocol use for the treatment of infections by carbapenem-resistant gram-negative bacteria: an Italian multicentre real-life experience","volume":"78","author":"Piccica","year":"2023","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.jinf.2026.106821_bib41","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02142-21","article-title":"Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant acinetobacter baumannii","volume":"66","author":"Falcone","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jinf.2026.106821_bib42","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1186\/s12879-024-09979-6","article-title":"Correction: comparison of cefiderocol and colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review with meta-analysis and trial sequential analysis","volume":"24","author":"Zhan","year":"2024","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jinf.2026.106821_bib43","article-title":"How to treat carbapenem-resistant Acinetobacter baumannii Infections","author":"Cascio","year":"2026","journal-title":"Curr Knowl Personal Viewp L Pipit\u00f2 D L Paterson (Eds)"},{"key":"10.1016\/j.jinf.2026.106821_bib44","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.jinf.2026.106821_bib45","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.jinf.2026.106821_bib46","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01063-24","article-title":"treatment strategies: a review of therapeutic challenges and considerations","volume":"69","author":"Kubin","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.jinf.2026.106821_bib47","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac092","article-title":"Novel combination therapy for extensively drug-resistant","volume":"9","author":"Holger","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"10.1016\/j.jinf.2026.106821_bib48","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1469-0691.2004.00987.x","article-title":"Synergic in-vitro activity of imipenem and sulbactam against acinetobacter baumannii","volume":"10","author":"Choi","year":"2004","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.jinf.2026.106821_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics11010033","article-title":"An evidence-based multidisciplinary approach focused on creating algorithms for targeted therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by","volume":"11","author":"Gatti","year":"2021","journal-title":"Antibiotics"},{"issue":"2","key":"10.1016\/j.jinf.2026.106821_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106723","article-title":"Clinical efficacy and safety of cefiderocol for resistant Gram-negative infections: a real-life, single-centre experience","volume":"61","author":"Karruli","year":"2023","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"10.1016\/j.jinf.2026.106821_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics12040746","article-title":"Cefiderocol efficacy in a real-life setting: single-centre retrospective study","volume":"12","author":"Palermo","year":"2023","journal-title":"Antibiotics"},{"issue":"6","key":"10.1016\/j.jinf.2026.106821_bib52","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s10096-024-04833-8","article-title":"Clinical effectiveness of cefiderocol for the treatment of bloodstream infections due to carbapenem-resistant Acinetobacter baumannii during the COVID-19 era: a single center, observational study","volume":"43","author":"Oliva","year":"2024","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"11","key":"10.1016\/j.jinf.2026.106821_bib53","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/phar.2334","article-title":"Compassionate Use of Cefiderocol in the treatment of an intraabdominal infection due to multidrug-resistant pseudomonas aeruginosa: a case report","volume":"39","author":"Stevens","year":"2019","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.jinf.2026.106821_bib54","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00948-19","article-title":"Coinfections of two strains of NDM-1- and OXA-232-Coproducing Klebsiella pneumoniae in a kidney transplant patient","volume":"64","author":"Contreras","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.jinf.2026.106821_bib55","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/phar.2704","article-title":"Safety and efficacy of cefiderocol for off-label treatment indications: a systematic review","volume":"42","author":"Babidhan","year":"2022","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.jinf.2026.106821_bib56","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa185","article-title":"Cefiderocol for extensively drug-resistant gram-negative bacterial infections: real-world experience from a case series and review of the literature","volume":"7","author":"Zingg","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"10.1016\/j.jinf.2026.106821_bib57","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01872-19","article-title":"Long-term compassionate use of cefiderocol to treat chronic osteomyelitis caused by extensively drug-resistant pseudomonas aeruginosa and extended-spectrum-\u03b2-Lactamase-producing Klebsiella pneumoniae in a pediatric patient","volume":"64","author":"Alamarat","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.jinf.2026.106821_bib58","article-title":"Infective endocarditis associated with implantable cardiac device by Metallo-\u03b2-Lactamase-producing pseudomonas aeruginosa, successfully treated with source control and cefiderocol plus imipenem","volume":"67","author":"Tascini","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.jinf.2026.106821_bib59","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.3390\/antibiotics11121686","article-title":"Successful treatment of Aortic Endocarditis by","volume":"11","author":"La Bella","year":"2022","journal-title":"Antibiotics"},{"issue":"11","key":"10.1016\/j.jinf.2026.106821_bib60","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/cid\/ciy963","article-title":"Compassionate use of cefiderocol as adjunctive treatment of native aortic valve endocarditis due to extremely drug-resistant pseudomonas aeruginosa","volume":"68","author":"Edgeworth","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.jinf.2026.106821_bib61","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3390\/antibiotics13050453","article-title":"Role of cefiderocol in multidrug-resistant gram-negative central nervous system infections: real life experience and state-of-the-art","volume":"13","author":"Sollima","year":"2024","journal-title":"Antibiotics"},{"issue":"5","key":"10.1016\/j.jinf.2026.106821_bib62","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/cid\/ciaf071","article-title":"The effectiveness of newer beta-lactams for the treatment of antimicrobial-resistant gram-negative meningitis","volume":"80","author":"Hsu","year":"2025","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.jinf.2026.106821_bib63","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1093\/jac\/dkac248","article-title":"Plasma and cerebrospinal fluid concentrations of cefiderocol during successful treatment of carbapenem-resistant acinetobacter baumannii meningitis","volume":"77","author":"Kufel","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.jinf.2026.106821_bib64","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3390\/microorganisms9020282","article-title":"The Cefiderocol French study group, susceptibility testing is key for the success of cefiderocol treatment: a retrospective cohort study","volume":"9","author":"Bleibtreu","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.jinf.2026.106821_bib65","article-title":"Resistance mechanisms and therapeutic strategies for\u00a0Pseudomonas aeruginosa infections","volume":"12","author":"Meletis","year":"2025","journal-title":"Ther Adv Infect Dis"},{"issue":"5","key":"10.1016\/j.jinf.2026.106821_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/idr17050112","article-title":"A retrospective study of cefiderocol utilization and associated outcomes at an academic medical center","volume":"17","author":"Rauch","year":"2025","journal-title":"Infect Dis Rep"},{"issue":"10","key":"10.1016\/j.jinf.2026.106821_bib67","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.3390\/antibiotics11101352","article-title":"vitro Activity of Cefiderocol and Comparators against Carbapenem-Resistant Gram-Negative Pathogens from France and Belgium","volume":"11","author":"Oueslati","year":"2022","journal-title":"Antibiot (Basel)"},{"issue":"11","key":"10.1016\/j.jinf.2026.106821_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics14111057","article-title":"Cefiderocol comparative resistance and clinical predictors in CRE-BSI: data from an OXA-48-Endemic region with rising OXA-48\/NDM coproducers","volume":"14","author":"Dumlu","year":"2025","journal-title":"Antibiotics"},{"issue":"2","key":"10.1016\/j.jinf.2026.106821_bib69","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijantimicag.2018.10.007","volume":"53","author":"Kazmierczak","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.jinf.2026.106821_bib70","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00497-24","article-title":"Tackling the unyielding: testing two novel approaches against NDM-producing Enterobacterales and","volume":"13","author":"Bakthavatchalam","year":"2025","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jinf.2026.106821_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2025.1490372","article-title":"Carbapenem treatment options for metallo-beta-lactamase: drug screening and dose optimization of meropenem-based combinations against NDM- or IMP-producing","volume":"16","author":"Che","year":"2025","journal-title":"Front Microbiol"},{"issue":"12","key":"10.1016\/j.jinf.2026.106821_bib72","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad627","article-title":"Real-life data on cefiderocol efficacy and safety to treat multidrug-resistant","volume":"10","author":"Campogiani","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"10.1016\/j.jinf.2026.106821_bib73","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s10096-025-05109-5","article-title":"Cefiderocol treatment for patients infected by Stenotrophomonas maltophilia, Burkholderia cepacia complex and Achromobacter spp.: subgroup analysis from the PERSEUS study","volume":"44","author":"Torre-Cisneros","year":"2025","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"3","key":"10.1016\/j.jinf.2026.106821_bib74","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s40121-025-01117-2","article-title":"S.G.Y.I.G.o.t.S.I.T. Antinfettiva), cefiderocol for the treatment of nosocomial bloodstream infections caused by stenotrophomonas maltophilia: a case series and literature review","volume":"14","author":"Vena","year":"2025","journal-title":"Infect Dis Ther"},{"issue":"2","key":"10.1016\/j.jinf.2026.106821_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106611","volume":"60","author":"Tiseo","year":"2022","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.jinf.2026.106821_bib76","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1186\/s12879-024-09700-7","article-title":"Outcomes of inadequate empiric therapy and timing of newer antibacterial therapy in hospitalized adults with culture-positive Enterobacterales and Pseudomonas aeruginosa: a multicenter analysis","volume":"24","author":"Riccobene","year":"2024","journal-title":"BMC Infect Dis"},{"issue":"3","key":"10.1016\/j.jinf.2026.106821_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.01.012","article-title":"Cefiderocol either in monotherapy or combination versus best available therapy in the treatment of carbapenem-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis","volume":"88","author":"Onorato","year":"2024","journal-title":"J Infect"},{"issue":"4","key":"10.1016\/j.jinf.2026.106821_bib78","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445326001477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445326001477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:12:01Z","timestamp":1790601121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445326001477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0163445326001477"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2026.106821","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cefiderocol in clinical practice: From randomised trials to real-world evidence in the management of multidrug-resistant Gram-negative bacterial infections","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2026.106821","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106821"}}